A Phase 1-2 Study of Lutetium-FAP for People With Advanced Pancreatic Cancer

Full Title

LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor

Purpose

Researchers are assessing Lutetium-FAP for people with advanced pancreatic cancer. Lutetium-FAP is a drug with a radioactive part attached. It targets cancer cells that make a protein called FAP, which may help cancer grow and survive. Lutetium-FAP combines a radiation-emitting metal with a tumor-targeting agent to deliver radiation into a tumor and destroy cancer cells.

If you take part in this study, you will get one of these treatments:

• Lutetium-FAP alone (for people who have had up to 2 prior regimens of cancer therapy)
• Lutetium-FAP with mFOLFIRINOX (for people who have had no prior cancer treatment)

mFOLFIRINOX is a combination of standard chemotherapy drugs used to treat people with pancreatic cancer.  

Contact

For more information or to see if you can join this study, please call Dr. Fiyinfolu Balogun’s office at 646-888-6964.